[A18-13] Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56

Last updated 05.04.2018

Project no.:

Commission awarded on 19.02.2018 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Kidneys and urinary system


Adults with advanced renal cell carcinoma after targeted therapy against vascular endothelial growth factor (VEGF)

Result of dossier assessment:

No change in the conclusion compared with A17-56


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2018-04-05 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.